THE USAGE COMPARISON OF CEFTRIAXONE AND CHLORAMPHENICOL FOR TYPHOID FEVER TREATMENT: AN EVIDENCE BASED CASE REPORT
Downloads
Typhoid fever is a disease caused by the gram-negative bacterium Salmonella typhi. Since its introduction in 1949, chloramphenicol has become the first-line treatment of typhoid fever for decades. Until now, chloramphenicol is still the first line treatment of typhoid fever in rural areas in Indonesia, due to its low cost. However, in addition to the problem of bacterial resistance, chloramphenicol is known to cause some side effect such as bone marrow suppression. Currently, many other antibiotics are used as the regimens for the treatment of typhoid fever, one of which is ceftriaxone. However, there are evidences on reemergence of chloramphenicol sensitivity in typhoid fever treatment. This report is created to answer the clinical question on whether ceftriaxone is more effective compared to chloramphenicol as the first-line treatment of typhoid fever. A structured search was performed on PubMed, EBSCO, and ScienceDirect and after a screening process and appraisal using the criteria from Center of Evidence Based Medicine at Oxford University, only one article was selected. The article shows higher efficacy of ceftriaxone in term of defervescence rate (P = 0.0001). No other study that compares the efficacy of ceftriaxone and chloramphenicol for typhoid fever treatment during the last ten years could be found during article searching. In conclusion, ceftriaxone shows better efficacy in the treatment of typhoid fever compared to chloramphenicol but with the rise of microbial sensitivity to chloramphenicol in recent years, more studies on this topic are needed to support this conclusion.
Herawati MH, Ghani L. Hubungan Faktor Determinan dengan Kejadian Tifoid di Indonesia Tahun 2007 (Association of Determinant Factors with Prevalence of Typhoid in Indonesia). 2009;XIX(4):165–73.
Longo DL, Harrison TR, Kasper D, Jameson J, Fauci A, Hauser S, et al. Harrison's principles of internal medicine. 18th ed. /. United States: New York : McGraw-Hill, 2012; 2012. 1277 p.
Department of Vaccines and Biologicals. Background Document: The Diagnosis, Treatment, and Prevention of Typhoid Fever. World Heal Organ. 2003;19–20.
Sudoyo AW, Bambang Setiyohadi, Alwi I, Simadibrata M, Setiati S. Buku Ajar Ilmu Penyakit Dalam Edisi V. 2009. 2797-2801 p.
Bhatia J, Mathur A, Arora M. Reemergence of Chloramphenicol Sensitivity in Enteric Fever. Med J Armed Forces India. 2007 Jul;63(3):212–4.
Harish BN, Menezes GA. Preserving efficacy of chloramphenicol against typhoid fever in a tertiary care hospital, India. WHO South-East Asia Reg Reg Heal Forum. 2011;Volume 15(Number 1):92–6.
Butler T. Treatment of typhoid fever in the 21st century: promises and shortcomings. Clin Microbiol Infect. 2011 Jul;17(7):959–63.
Jog S, Soman R, Singhal T, Rodrigues C, Mehta A, Dastur FD. Enteric fever in Mumbai--clinical profile, sensitivity patterns and response to antimicrobials. J Assoc Physicians India. 2008 Apr;56:237–40.
Krishnan P, Stalin M, Balasubramanian S. Changing trends in antimicrobial resistance of Salmonella enterica serovar typhi and salmonella enterica serovar paratyphi A in Chennai. Indian J Pathol Microbiol. 52(4):505–8.
Hammad OM, Hifnawy T, Omran D, El Tantawi MA, Girgis NI. Ceftriaxone Versus Chloramphenicol for Treatment of Acute Typhoid Fever. Life Sci J. 2011;8(2):100–5.
The Indonesian Journal of Tropical and Infectious Disease (IJTID) is a scientific peer-reviewed journal freely available to be accessed, downloaded, and used for research. All articles published in the IJTID are licensed under the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License, which is under the following terms:
Attribution ” You must give appropriate credit, link to the license, and indicate if changes were made. You may do so reasonably, but not in any way that suggests the licensor endorses you or your use.
NonCommercial ” You may not use the material for commercial purposes.
ShareAlike ” If you remix, transform, or build upon the material, you must distribute your contributions under the same license as the original.
No additional restrictions ” You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.
